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Abstract
Introduction. Liver transplantation (LT) is at high-risk for cardiovascular events. Therefore, candidates have pre-operative 
cardiological diagnostics to lower the risk of post-surgical complications. The purpose of this study was to analyse 
a cohort of liver recipients from one transplant centre in Poland, to evaluate the accuracy of pre-transplant cardiac as-
sessment in the prediction of short- and long-term outcomes, and to investigate any correlation between cardiovascular 
events and patient characteristics.
Material and methods. This retrospective study was conducted among 141 consecutive patients evaluated for LT in 
2017–2018. Recipients under the age of 40 were excluded. All candidates had electrocardiography, echocardiography 
and their functional capacity was assessed. Patients with metabolic equivalent < 4 or clinical indications were subjected 
to stress echocardiography. Patients underwent at least one year post-transplant follow-up to detect late cardiovascular 
complications.
Results. 141 patients were evaluated, and 116 patients were finally enlisted. Four recipients were disqualificated for 
cardiological reasons, and the remaining 21 were rejected for non-cardiological reasons. There were no early cardio-
vascular complications in a 30-day follow-up. Late cardiovascular complications were observed in four transplanted 
patients. Diabetes increases cardiovascular complications (p = 0.001).
Conclusion. The applied cardiological diagnostics allowed early cardiovascular events to be avoided. Very careful post- 
-transplant monitoring is indicated, particularly in diabetes patients, due to the greater risk of long-term complications. 
Post-transplant immunosuppression and liver function recovery may contribute to this.
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Introduction
Cardiovascular disease (CVD) is a group of diseases that 
involve the heart and/or blood vessels. CVD includes co-
ronary artery disease (CAD) which is a disorder resulting 
from impaired blood supply to the heart muscle caused 
by the narrowing of coronary vessels by the formation of 
atherosclerotic plaques. This leads to myocardial ischaemia 
because the delivery of oxygen and nutrients to the myo-
cardium is insufficient [1]. Atherosclerotic changes in the 
vessels develop over the years. Their severity depends on 
genetic predispositions and the presence of risk factors 
for CAD: see Table 1 [2].
In patients with cirrhosis, cardiac complications 
develop and intensify with the progression of liver disease. 
Hyperdynamic circulation is the result of peripheral 
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CAD risk factors, have a good perioperative prognosis and 
do not require additional testing [8, 10].
Coronary angiography, the gold standard for coronary 
artery assessment, is rarely performed due to the invasive 
nature of the examination and the high risk of complications 
in patients with end-stage liver failure, such as the greater 
risk of bleeding than in the general population with a more 
frequent need for transfusion of blood products [11], in-
fections and contrast-induced nephropathy, as well as the 
high sensitivity of non-invasive tests.
The aim of this study was to investigate the accuracy 
of pre-transplant cardiovascular assessment in predicting 
short- and long-term cardiovascular outcomes, and to ana-
lyse the correlation between cardiovascular events and pa-
tient characteristics.
Material and methods
The study group consisted of 141 consecutive cirrhotic 
patients aged from 40 to 70 years, who were hospitalised 
in 2017–2018 in one transplant centre for the purpose of 
qualifying for LT. Recipients under 40 years of age were 
excluded due to the low incidence of cardiovascular disease 
in this group.
In this retrospective assessment, the occurrence of 
CAD was analysed and risk factors were examined on 
the basis of medical tests (fasting lipids levels, gluco-
se and creatinine levels) and cardiological studies. An 
ECG and an echocardiography with the evaluation of left 
ventricular ejection fraction (LVEF) and diastolic fun-
ction were performed in all subjects. In addition, a DSE 
was performed in patients with a low functional capa-
city (assessed during the interview with the patient) or 
with clinical manifestation of CAD (ischaemic changes 
in ECG or segmental contractility abnormalities in the 
heart ultrasound) [12].
DSE was performed after stopping the β-blocker three 
days earlier to allow the target heart rate to be obtained. 
The baseline characteristics of the study cohort are set out 
in Table 2. The table excludes patients disqualified for non-
-cardiological reasons. Early cardiovascular complications 
(within 30 days post-op) and late complications (30+ days 
after surgery) were analysed.
Statistical analyses were carried out using the R pro-
gram. All parameters are presented as mean (standard de-
viation) or counts (percentages) where appropriate. The ef-
fect of diabetes on the appearance of cardiovascular events 
was assessed using Fisher’s test. Statistical significance 
level was assumed for p-value < 0.05.
Results
The main indication for liver transplantation was end-stage 
chronic hepatitis C.
vasodilation after overproduction of nitric oxide due 
to portal hypertension. Reduced vascular resistance 
increases cardiac output. This leads to the development 
of hepatic cardiomyopathy due to impairment of left 
ventricle ejection fraction, or insufficient cardiac output in 
response to physical exertion, stress or pharmacological 
stimulation. Additionally, diastolic disorders appear as 
well as electrical dysfunction of the cardiac conduction 
system during the repolarisation period [QT prolongation 
in electrocardiography (ECG)]. Hepatic cardiomyopathy 
develops irrespective of underlying disease aetiology. 
Usually clinically silent cardiomyopathy manifests itself in 
response to stress, which in this case may be prolonged 
surgery [3, 4].
Therefore, patients with liver cirrhosis during evalua-
tion for liver transplantation (LT), according to the Europe-
an Cardiac Society (ESC) recommendations, undergo a de-
tailed cardiac diagnostics due to the extent of surgery and 
the existence of multiple co-morbidities, which are also risk 
factors for CAD. Liver transplant candidates are in the high 
risk group of cardiovascular events in the perioperative pe-
riod (a greater than 5% 30-day risk of myocardial infarction, 
cardiac arrest, life-threatening arrhythmias, stroke and de-
ath from cardiovascular causes) due to vascular changes 
after transplantation such as increased systemic vascular 
resistance, decreased cardiac output and increased pul-
monary capillary wedge pressure [5–8].
Preoperative tests for high risk surgery, such as LT, 
include ECG and resting echocardiography [9]. Additionally, 
the patient’s functional capacity, measured in metabolic 
equivalents (METs) of tasks, is taken into account. When 
METs are below 4, which in practice means an inability to walk 
up two flights of stairs, or when the clinical picture suggests 
the presence of CAD, extra stress tests are carried out.
Non-invasive tests, predicting long-term mortality 
(more than 30 days after surgery) from cardiac events 
include dobutamine stress echocardiography (DSE), cardiac 
magnetic resonance, and myocardial perfusion imaging 
(MPI). Patients with optimal exercise tolerance, even with 
Table 1. Risk factors for coronary artery disease
Non-modifiable Modifiable
Age High blood pressure
Sex Smoking







Diseases of arteries (atherosclerosis 
of carotid arteries, arteries of lower limbs)
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Twenty one patients were excluded from the transplant 
list for non-cardiological reasons.
Among 120 patients included in the analysis, 
62 (51,67%) had at least two risk factors for CAD. Among 
those patients were 42 men (67.74%) and 20 women 
(32.26%). Thirty one patients were burdened with more 
than two risk factors. The most frequent risk factors were 
hypertension, diabetes, smoking, and obesity.
During preoperative cardiological diagnosis, 24 dobu-
tamine stress echo tests were performed. Four patients 
(two women and two men) were disqualified from LT for 
cardiological reasons. DSE was positive in two cases. One 
patient initially had a segmental contractility disorder in 
the resting echocardiography. In one case, severe aortic 
stenosis was diagnosed. The characteristics of these pa-
tients are set out in Table 3. It is worth noting that all of 
them suffered from diabetes.
There were no cardiovascular events during, or within 
30 days after, transplantation. In four male patients, car-
diovascular events in the form of myocardial infarction were 
revealed during long-term follow-up (all within the first year 
of observation). There were no cardiovascular incidents in 
women. The characteristics of patients who had a heart 
attack are set out in Table 4.
Among many risk factors in patients diagnosed with co-
ronary artery disease during transplant qualification and 
in patients with late cardiovascular complications, dia-
betes deserves attention, because it occurred in 7/8 pa-
tients (87.5%).
Diabetes increases the risk of cardiovascular compli-
cations in patients with liver cirrhosis (p value = 0.001).
Table 2. Baseline characteristics of study group
Parameter All patients 
N = 120
Age at time of qualification
Mean [years ± SD] 57 [± 6.91]
Median [range] 59 [40–70]
Female, N [%] 45 (37.5%)
Male, N [%] 75 (62.5%)
Aetiology of liver disease
Hepatitis C 46 (38.33%)
Alcoholism 31 (25.83%)





Risk factors of CAD
Hypertension 46 (38.33%)




Chronic kidney disease 11 (9.17%)
Peripheral artery disease/history  
of thromboembolism
6 (5.0%)
SD — standard deviation; PBC — primary biliary cirrhosis; PSC — primary sclerosing cholangitis; 
CAD — coronary artery disease
Table 3. Characteristics of patients disqualified from liver transplantation (LT)
Studied parameter Patient 1 Patient 2 Patient 3 Patient 4
Age at time  
of qualifying for LT
64 56 63 67
Cause of liver cirrhosis HBV Alcoholism Alcoholism HCV














Positive Not performed due to 
severe aortic stenosis 
in transthoracic ultra-
sound
Positive Ischaemic negative, but 
new segmental contractility 
disorder in resting echocar-
diography
Coronary angiography Multivessel coronary 
artery disease
No coronary artery 
stenosis
Not carried out 
(patient’s decision)
Multivessel coronary artery 
disease
HBV — hepatitis B virus; HCV — hepatitis C virus
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Discussion
The pre-operative cardiological evaluation used in our study 
allowed us to avoid short-term cardiovascular complica-
tions, because 100% of patients survived the early peri-
operative period, and no cardiovascular events were noted.
Late cardiovascular complications occurred in a few 
patients despite correct results during preoperative tests, 
including negative DSE which has a confirmed high negati-
ve predictive value in the diagnosis of CAD [12, 13]. These 
cases mainly concerned patients with diabetes. Liver trans-
plant recipients are at risk of worsening glucose levels af-
ter surgery among others because of immunosuppressive 
treatment (glucocorticosteroids, calcineurin inhibitors and 
mammalian target of rapamycin inhibitors) that increases 
liver gluconeogenesis after recovery and reduces tissue glu-
cose catabolism [14–16]. For the above reasons, the risk of 
hyperglycaemia is also increased in non-diabetic patients 
(NODAT, new onset diabetes after transplantation) [17–19].
Another problem in liver transplant recipients is obesity. 
More than 40% of recipients become overweight or obese 
within the first year post-LT [17, 18]. Due to the changes 
in transplant indications observed in recent years (the in-
creasing incidence of non-alcoholic fatty liver disease as 
a cause of liver cirrhosis), the risk of metabolic syndrome 
in liver recipients, and thus diabetes, increases [20].
We must underline that in our study group there were 
no clearly diagnosed cases of non-alcoholic steatohepatitis 
(NASH) as an indication for liver transplantation. However, 
we cannot rule out that so-called cryptogenic cirrhosis 
(three cases) or cirrhosis of unknown aetiology (seven 
cases) had been the result of burnt out steatohepatitis, 
but such an aetiology was not confirmed in the explant 
pathology. Lack of NASH cases in our series may partly 
explain the low incidence of CAD in the studied group.
The prevalence of diabetes increases from 15% be-
fore surgery to 40% after transplantation [21]. There-
fore, a careful post-transplant observation towards CAD 
is mandatory, especially in patients with previously diag-
nosed diabetes, but also in patients with risk factors for 
diabetes or new-onset diabetes mellitus after transplan-
tation (NODAT).
Likewise, lipid levels are lower in end-stage liver dis-
ease than in the general Polish population based on 
data from the NATPOL 2011 study [22]. In male patients 
from the study group, mean value of total cholesterol was 
154.7 mg/dL versus 212.4 mg/dL in the general popula-
tion, females 168.0 mg/dL vs. 214.4 mg/dL, respectively. 
After surgery, the liver regains its ability to produce choles-
terol and thereby lipid levels significantly increase, and this 
phenomenon also requires further attention.
Therefore, the post-transplant assessment should al-
ways include regular monitoring of glucose level, HbA1c and 
lipid parameters, as well as the performance of re-imaging 
tests (resting and stress echocardiography) if necessary.
Conclusions
The preoperative cardiological diagnostics before liver 
transplantation is effective because it allows the avoidance 
of short-term death and complications from cardiovascular 
causes in most instances. In this study, there were no car-
diovascular events within 30 days of surgery. The presence 
of diabetes is associated with a higher risk of long-term 
cardiac deaths, and therefore requires a more accurate 
assessment, both before and after transplantation.
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Table 4. Characteristics of patients with late cardiovascular complications
Studied parameter Patient 1 Patient 2 Patient 3 Patient 4
Age at time of qualifying for LT 66 64 59 70
Cause of liver cirrhosis HBV HCV Alcoholism Other  
(haemochromatosis)












Dobutamine stress echo (DSE) 
in preoperative period
Negative Negative Not performed due to 
good exercise tolerance
Not performed due to 
good exercise tolerance
Time from LT to cardiac death 6 months 42 days 3 months 10 months
LT — liver transplantation; HBV — hepatitis B virus; HCV — hepatitis C virus
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Streszczenie
Wstęp. Transplantacja wątroby (LT) należy do operacji obarczonych dużym ryzykiem powikłań sercowo-naczyniowych, 
dlatego pacjenci kwalifikowani do przeszczepienia są poddawani ocenie kardiologicznej, by obniżyć ryzyko powikłań 
pooperacyjnych. Celem badania była analiza grupy potencjalnych biorców wątroby z jednego ośrodka transplantacyjnego 
w Polsce i ocena wpływu kwalifikacji kardiologicznej na występowanie wczesnych i późnych powikłań sercowo-naczynio-
wych. Badano również korelacje zdarzeń sercowo-naczyniowych z charakterystyką tych pacjentów.
Materiał i metody. Retrospektywnie analizowano 141 kolejnych pacjentów kwalifikowanych do operacji w latach 
2017–2018. Z analizy wykluczono osoby poniżej 40. roku życia. U wszystkich kandydatów wykonano elektrokardiografię 
i echo serca oraz oceniano ich wydolność fizyczną. U pacjentów z małą wydolnością fizyczną, poniżej 4 ekwiwalentów 
metabolicznych, lub z kliniczną manifestacją choroby wieńcowej przeprowadzono echokardiografię obciążeniową z po-
daniem dobutaminy. Pacjentów poddano co najmniej rocznej obserwacji po przeszczepieniu w celu wykrycia późnych 
powikłań sercowo-naczyniowych.
Wyniki. Przeanalizowano dane dotyczące 141 chorych, spośród których ostatecznie 116 zostało zakwalifikowanych do 
operacji. Czterech chorych zdyskwalifikowano w toku diagnostyki kardiologicznej, a 21 odrzucono z przyczyn niekardiolo-
gicznych. Nie stwierdzono powikłań wczesnych. Późne komplikacje sercowo-naczyniowe wystąpiły u 4 biorców. Cukrzyca 
zwiększa ryzyko powikłań sercowo-naczyniowych (p = 0,001).
Wnioski. Zastosowana diagnostyka kardiologiczna pozwoliła uniknąć powikłań sercowo-naczyniowych w okresie oko-
łooperacyjnych. Zaleca się dalszą dokładną obserwację biorców, szczególnie cierpiących na cukrzycę, ze względu na 
wyższe ryzyko odległych powikłań sercowo-naczyniowych. Odpowiadać za to może między innymi potransplantacyjna 
immunosupresja oraz powrót funkcji metabolicznej wątroby.
Słowa kluczowe: choroba układu sercowo-naczyniowego, zdarzenia sercowo-naczyniowe, transplantacja wątroby, 
NODAT, NATPOL 2011
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